Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK

Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK

By Dhirendra Tripathi

Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 6% in Monday's premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.

The trial had 29,960 participants across the U.S. and Mexico.